HWK 007
Alternative Names: HWK-007Latest Information Update: 30 May 2025
At a glance
- Originator WuXi Biologics
- Developer Whitehawk Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 07 Apr 2025 Whitehawk Therapeutics plans a phase I trial for Ovarian cancer and Non small lung cancer (Parenteral) in second half of 2025 (Whitehawk Therapeutics pipeline, April 2025)
- 19 Mar 2025 Preclinical trials in Non-small cell lung cancer in USA (Parenteral)
- 19 Mar 2025 Preclinical trials in Ovarian cancer in USA (Parenteral)